Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Narcolepsy Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Narcolepsy Overview | 9 | 1 |
| Pipeline Products for Narcolepsy Comparative Analysis | 10 | 1 |
| Narcolepsy Therapeutics under Development by Companies | 11 | 1 |
| Narcolepsy Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Narcolepsy Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Narcolepsy Products under Development by Companies | 16 | 1 |
| Narcolepsy Products under Investigation by Universities/Institutes | 17 | 1 |
| Narcolepsy Companies Involved in Therapeutics Development | 18 | 12 |
| Bioprojet SCR | 18 | 1 |
| Evotec AG | 19 | 1 |
| Flamel Technologies S.A. | 20 | 1 |
| H.A.C. Pharma | 21 | 1 |
| Heptares Therapeutics Limited | 22 | 1 |
| Jazz Pharmaceuticals Plc | 23 | 1 |
| NLS Pharma Group | 24 | 1 |
| Ono Pharmaceutical Co., Ltd. | 25 | 1 |
| Sanofi | 26 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 27 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 28 | 1 |
| Theranexus SAS | 29 | 1 |
| Narcolepsy Therapeutics Assessment | 30 | 8 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Combination Products | 31 | 1 |
| Assessment by Target | 32 | 2 |
| Assessment by Mechanism of Action | 34 | 2 |
| Assessment by Route of Administration | 36 | 1 |
| Assessment by Molecule Type | 37 | 1 |
| Drug Profiles | 38 | 24 |
| (flecainide acetate + modafinil) Drug Profile | 38 | 2 |
| arbaclofen Drug Profile | 40 | 1 |
| JZP-386 Drug Profile | 41 | 1 |
| mazindol Drug Profile | 42 | 1 |
| mazindol Drug Profile | 43 | 1 |
| NLS-3 Drug Profile | 44 | 1 |
| ONO-4127 Drug Profile | 45 | 1 |
| Pentylenetetrazol Drug Profile | 46 | 1 |
| pitolisant Drug Profile | 47 | 2 |
| SAR-110068 Drug Profile | 49 | 1 |
| SKL-N05 Drug Profile | 50 | 3 |
| Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders Drug Profile | 53 | 1 |
| Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy Drug Profile | 54 | 1 |
| Small Molecules to Agonize Orexin Receptor for EDS and Narcolepsy Drug Profile | 55 | 1 |
| Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders Drug Profile | 56 | 1 |
| sodium oxybate Drug Profile | 57 | 2 |
| sodium oxybate Drug Profile | 59 | 2 |
| TS-091 Drug Profile | 61 | 1 |
| Narcolepsy Dormant Projects | 62 | 1 |
| Narcolepsy Discontinued Products | 63 | 1 |
| Narcolepsy Product Development Milestones | 64 | 10 |
| Featured News &Press Releases | 64 | 1 |
| Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218 | 64 | 1 |
| Oct 04, 2016: Theranexus Has Obtained an Orphan Drug Designation from the FDA for THN102 in the Treatment of Narcolepsy | 64 | 1 |
| Jul 11, 2016: Mazindol Granted Orphan Drug Designation in the US &Europe for Treatment of Narcolepsy | 65 | 1 |
| Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting | 65 | 1 |
| May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness | 66 | 1 |
| Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate | 67 | 1 |
| Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep | 67 | 1 |
| Nov 20, 2015: Narcolepsy treatment recommended for approval | 68 | 1 |
| Oct 19, 2015: Theranexus: Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders, in partnership with the French Armed Forces Biomedical Research Institute (IRBA) | 69 | 1 |
| Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies | 69 | 1 |
| Jun 04, 2015: Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem(sodium oxybate) at SLEEP 2015 | 70 | 1 |
| May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update | 71 | 1 |
| Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate | 71 | 1 |
| Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update | 72 | 1 |
| Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy | 73 | 1 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |
